Tequin is the drug used to treat pneumonia, bronchitis and other infections. Bristol-Myers Squibb Co. (BMY) is manufacturing the drug.
The U.S. Food and Drug Administration said that the drug would carry stronger warnings about the rare life-threatening events from blood-sugar changes due to this drug.
This is the outcome after FDA received continued reports of serious cases of hypoglycemia (low blood sugar) and hyperglycemia in patients receiving Tequin.
The drug got its approval in 1999 but since then there has been rare cases of life-threatening events occurring globally in patients treated with the drug.
Most of the cases were reversed but a few were fatal.
The warning that was included recently said that the drug is no longer recommended for use in people with diabetes.
Apart from this stronger warning are provided with additional information to health-care professionals about the rare life-threatening events from blood-sugar changes.
But the FDA said that it would continue scrutinizing Tequin's safety so as to ensure that its benefits outweigh the risks to patients.